GLA and Fabry disease: Previous preclinical evaluations of gene therapy approaches in FD mice (Gla KO) have shown that AAV2- and AAV1-mediated gene therapy results in suboptimal substrate clearance in key target tissues of FD mice, particularly in the kidney [30–32].